NCM Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

NCM Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$458K	Sell	3,584 -36	-1%	-$4.49K	0.16%	118
2025 Q4	$441K	Buy	3,620 +4	+0.1%	+$459	0.16%	121
2025 Q3	$362K	Hold	3,616	–	–	0.14%	134
2025 Q2	$300K	Sell	3,616 -100	-3%	-$7.98K	0.12%	144
2025 Q1	$301K	Sell	3,716 -50	-1%	-$4.47K	0.14%	142
2024 Q4	$339K	Hold	3,766	–	–	0.15%	134
2024 Q3	$372K	Hold	3,766	–	–	0.18%	122
2024 Q2	$349K	Hold	3,766	–	–	0.18%	119
2024 Q1	$357K	Buy	3,766 +21	+0.6%	+$1.95K	0.2%	116
2023 Q4	$334K	Sell	3,745 -50	-1%	-$3.71K	0.2%	117
2023 Q3	$277K	Hold	3,795	–	–	0.2%	116
2023 Q2	$316K	Hold	3,795	–	–	0.22%	115
2023 Q1	$289K	Buy	3,795 +45	+1%	+$3.73K	0.22%	118
2022 Q4	$311K	Hold	3,750	–	–	0.21%	130
2022 Q3	$297K	Hold	3,750	–	–	0.22%	131
2022 Q2	$279K	Hold	3,750	–	–	0.2%	142
2022 Q1	$337K	Hold	3,750	–	–	0.21%	139
2021 Q4	$420K	Buy	+3,750	New	+$452K	0.37%	90

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

NCM Capital Management's XBI Position: Q1 2026 in Review

NCM Capital Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 0.99% in Q1 2026, selling an estimated $4.49K and leaving 3,584 shares worth $458K. The position accounts for 0.16% of the portfolio, ranked #118.

NCM Capital Management first reported a position in XBI in Q4 2021 and has held it in 18 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

NCM Capital Management held 3,584 shares of State Street SPDR S&P Biotech ETF worth $458K as of Q1 2026.
NCM Capital Management sold 36 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $4.49K.
State Street SPDR S&P Biotech ETF made up 0.16% of NCM Capital Management's portfolio in Q1 2026, its #118 holding.
NCM Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2021 and has held it in 18 quarters since.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on NCM Capital Management's 13F filing for Q1 2026, filed 15 May 2026.